Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci .

Ann Rheum Dis

Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany.

Published: August 2022

Download full-text PDF	Source
http://dx.doi.org/10.1136/annrheumdis-2020-218686	DOI Listing

Publication Analysis

treatment patients

patients inflammatory

inflammatory rheumatic

rheumatic diseases

diseases rituximab

rituximab carefully

carefully considered

considered sars-cov-2/covid-19

sars-cov-2/covid-19 pandemic

pandemic response

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!